XNASIINN
Market cap21mUSD
Dec 24, Last price
1.16USD
1D
0.10%
1Q
-7.84%
IPO
-75.55%
Name
Inspira Technologies Oxy BHN Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
43.85%
Rev. gr., 5y
%
Revenues
0k
P
Net income
-11m
L+182.01%
CFO
-10m
L+32.20%
Profile
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | (4,678) | |||||
Cost of revenue | 11,873 | 15,131 | 13,475 | |||
Unusual Expense (Income) | ||||||
NOPBT | (11,873) | (19,809) | (13,475) | |||
NOPBT Margin | 423.45% | |||||
Operating Taxes | (6,271) | 6 | ||||
Tax Rate | ||||||
NOPAT | (11,873) | (13,538) | (13,481) | |||
Net income | (11,286) 182.01% | (4,002) -76.40% | (16,961) 134.49% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 2,154 | 14,658 | ||||
BB yield | -16.80% | -66.40% | ||||
| Debt | ||||||
Debt current | 290 | 329 | 281 | |||
Long-term debt | 1,466 | 2,183 | 2,383 | |||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (5,605) | (11,391) | (21,085) | |||
| Cash flow | ||||||
Cash from operating activities | (9,756) | (7,380) | (7,877) | |||
CAPEX | (206) | (304) | (176) | |||
Cash from investing activities | 4,594 | (7,249) | (246) | |||
Cash from financing activities | 3,453 | (399) | 30,422 | |||
FCF | (11,872) | (13,694) | (14,627) | |||
| Balance | ||||||
Cash | 7,361 | 13,903 | 23,749 | |||
Long term investments | ||||||
Excess cash | 7,361 | 14,137 | 23,749 | |||
Stockholders' equity | 5,738 | 12,822 | 20,354 | |||
Invested Capital | 878 | 1,455 | 1,483 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 12,095 | 10,795 | 5,306 | |||
Price | 1.06 -17.83% | 1.29 -68.99% | 4.16 | |||
Market cap | 12,821 -7.93% | 13,925 -36.92% | 22,074 | |||
EV | 7,216 | 2,534 | 989 | |||
EBITDA | (11,762) | (19,448) | (13,238) | |||
EV/EBITDA | ||||||
Interest | 10 | 181 | 6 | |||
Interest/NOPBT | ||||||